These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 21080210

  • 1. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [Abstract] [Full Text] [Related]

  • 2. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.
    Peng T, Wu JR, Tong LJ, Li MY, Chen F, Leng YX, Qu R, Han K, Su Y, Chen Y, Duan WH, Xie H, Ding J.
    Acta Pharmacol Sin; 2014 Jul; 35(7):916-28. PubMed ID: 24858311
    [Abstract] [Full Text] [Related]

  • 3. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.
    Cancer Res; 2006 Sep 15; 66(18):9134-42. PubMed ID: 16982756
    [Abstract] [Full Text] [Related]

  • 4. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J, Huang L, Li X.
    Biochem Pharmacol; 2015 Sep 01; 97(1):51-61. PubMed ID: 26212540
    [Abstract] [Full Text] [Related]

  • 5. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
    Zhang X, Raghavan S, Ihnat M, Thorpe JE, Disch BC, Bastian A, Bailey-Downs LC, Dybdal-Hargreaves NF, Rohena CC, Hamel E, Mooberry SL, Gangjee A.
    Bioorg Med Chem; 2014 Jul 15; 22(14):3753-72. PubMed ID: 24890652
    [Abstract] [Full Text] [Related]

  • 6. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
    Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.
    Mol Cancer Ther; 2006 Jul 15; 5(7):1774-82. PubMed ID: 16891463
    [Abstract] [Full Text] [Related]

  • 7. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 15; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 8. Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity.
    Liu Z, Mao S, Li H, Liu W, Tao J, Lu Y, Dong H, Zhang J, Song C, Duan Y, Yao Y.
    Bioorg Chem; 2024 Oct 15; 151():107679. PubMed ID: 39094510
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
    Shi ZH, Liu FT, Tian HZ, Zhang YM, Li NG, Lu T.
    Bioorg Med Chem; 2018 Sep 01; 26(16):4735-4744. PubMed ID: 30121211
    [Abstract] [Full Text] [Related]

  • 10. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X, Raghavan S, Ihnat M, Hamel E, Zammiello C, Bastian A, Mooberry SL, Gangjee A.
    Bioorg Med Chem; 2015 May 15; 23(10):2408-23. PubMed ID: 25882519
    [Abstract] [Full Text] [Related]

  • 11. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.
    Mol Cancer Ther; 2011 May 15; 10(5):861-73. PubMed ID: 21441409
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, Kim HR, Koh JS, Lee J.
    Invest New Drugs; 2012 Apr 15; 30(2):518-23. PubMed ID: 21080208
    [Abstract] [Full Text] [Related]

  • 13. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
    Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, Yu Q, Long YQ.
    ChemMedChem; 2012 Apr 15; 7(4):680-93. PubMed ID: 22311585
    [Abstract] [Full Text] [Related]

  • 14. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
    Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J.
    PLoS One; 2009 Apr 15; 4(3):e4881. PubMed ID: 19293927
    [Abstract] [Full Text] [Related]

  • 15. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
    Park JS, Lee C, Kim HK, Kim D, Son JB, Ko E, Cho JH, Kim ND, Nan HY, Kim CY, Yoon S, Lee SH, Choi HG.
    Oncotarget; 2016 Dec 13; 7(50):83308-83318. PubMed ID: 27829217
    [Abstract] [Full Text] [Related]

  • 16. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
    Liang X, Wang B, Chen C, Wang A, Hu C, Zou F, Yu K, Liu Q, Li F, Hu Z, Lu T, Wang J, Wang L, Weisberg EL, Li L, Xia R, Wang W, Ren T, Ge J, Liu J, Liu Q.
    J Med Chem; 2019 Jan 24; 62(2):875-892. PubMed ID: 30565931
    [Abstract] [Full Text] [Related]

  • 17. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Pavana RK, Choudhary S, Bastian A, Ihnat MA, Bai R, Hamel E, Gangjee A.
    Bioorg Med Chem; 2017 Jan 15; 25(2):545-556. PubMed ID: 27894589
    [Abstract] [Full Text] [Related]

  • 18. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec 15; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

  • 19. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.
    Eur J Med Chem; 2013 Sep 15; 67():373-83. PubMed ID: 23900004
    [Abstract] [Full Text] [Related]

  • 20. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X, Yue GG, Liu M, Zuo Z, Lee JK, Li M, Tsui SK, Fung KP, Sun H, Pu J, Lau CB.
    Oncotarget; 2016 Dec 13; 7(50):82820-82835. PubMed ID: 27756875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.